call. to Novanta of on our Thank everybody, you, promises Ray. in quarter morning, both Good well delivering and performed for joining our profit revenue shareholder. the our second and thanks XXXX,
Our X% organic reported in a million X% basis. on and basis $XXX company year-over-year revenue, an on growth revenue delivered representing
Our was share year. million. Adjusted $X.XX was $X.XX, per adjusted X% from earnings was up which EBITDA last $XX
motion, Novanta's executed healthcare productivity Our capabilities favorable the in with a in on of than team revenue very precision photonics half a growing. laser-focused remain by proprietary faster medical industrial positioning structurally of Industry over climate. and deteriorating driven markets that spending medicine growing capital vision well diverse in are X.X, set and our We with market is secular trends. applications,
business potential investing surgery, growth We are robotic and material commercial to secular precision processing automation and enhance invasive minimally long-term our position in capabilities cycles technology in as robotics. proprietary sustainable innovation and growth DNA such applications surgery, strongly through advanced and sequencing,
planned launched new our smoke have quarter, with integrated In our insufflator a into see we RFID the functionality. new platforms expanded product robotic evacuation X of products to in continued second we To introduce solid success date, X momentum to new innovations introduced and the to customers. customer, medical with multiple year, latest products tremendous this see OR large our with and momentum surgery a efforts
XX% product New grew revenue over year-to-date year-over-year.
in years for new few a launched versus mid-single-digit the of the products last vitality time quarter from in index, first revenue the sales exceeded is which years, Our XX% ago. X percentages
operating performance. the to our sustained implementing benefits in design we growth design new quarter and we are increased half Novanta of strong early momentum expecting second All see by I'm driving all, XX%, as of accelerating team Our year-to-date over system, the in continue of by second our the XXXX. and proud in long-term wins the growth performance
technologies. second capital An quarter, In to the intelligent just X second X Change the and our with strategy we we expanding and element quarter, in proprietary closed Arges. third acquisitions, Med M&A. in into closed important strategy one, subsystems deployment of opportunity our accelerate We the saw tuck-in is Ingenia
on touch me each Let them of briefly.
earnings reported precision forward robotics with Ingenia strategically is tremendously is the acquisition solutions intelligent tuck-in motion of motion In subsystem reception servo applications. call, our drives. The encouraging. customers motion on on solutions The the and we developing selling acquisition Ingenia's important solutions team and phenomenal, of control control last small provides Ingenia a customers already Ingenia's in step and is through precision technology OEM Ingenia. automation the Novanta's high-power through of in customers GaN-based technology intelligent high-performance,
team portfolio the such pleased as that in and In digital another of is Med position and high-growth family surgery during data, referred to with each X video the patients to of to markets. OR, can couldn't for for where closed XK devices a into our The is integrated This sent with Novanta systems now, information over expands Change, our need part medical to images other out build a hospital tuck-in integrated connected our June, our growing data-generating adds capability also more the the strategy we of by operating important acquisition business. further and the segment Med little X room which surrounding small controlled portfolio a and Novanta the OR, user. Change MIS stored, be and month easily be the recording opportunity market. and aligns we the be acquisition to well
intelligent Arges and hour develops doubles End closed and Germany Arges Arges. laser and markets laser third manufacturing, high-growth medical segment. innovative is Novanta We sales scanning see as our I channels. sales strong technology capabilities applying located contribute intelligent in segment. for and dramatically growth we phenomenal a opportunities, in synergies our year, subsystems This very few and strategy Photonics into such medical through this which of July, Munich, beam additive XXXX ago, industrial accelerates Photonics adds and micromachining knowhow X our days a of and we I'm steering acquisition beyond. in the of our subsystem of applications. IP our of which proprietary capabilities breadth and north and will This advanced -- manufactures very strong our photonic applications engineering acquisition company to excited to will to funnel about visited of these materially
strong From activity. an we M&A pipeline perspective, and see increasing
will feel remain that fit we very While strategy. an opportunity disciplined accelerates on and we returns, arises strategic quickly move we if our
in let Now and seeing our overall the macroeconomic what on touch markets climate. me we're
of the broad-based, particularly but medical surgery. momentum full and saw invasive pleased minimally our double-digit very momentum quarter Momentum we and We growth businesses in our to Our to XXXX. that with continue is be are medical markets for the in year second expect robust. in robotic continue
functionality. integrated a and announced customer, Novanta is these gaining multiple see markets, large medical driven decline latest medical smoke with OR would surgery by innovation. a businesses, to into evacuation double-digit out insufflator with despite our a product share in like tremendous with with products point in achieving DNA momentum sequencing. multiple technologies year-over-year in we're I new expanded that We new also growth platforms our robotic double-digit
decelerating medical with the our engine uncertain to climate. as expect saw an industrial low-risk momentum consistent in Representing further in XXXX second a climate in our we serve spending revenue, macroeconomic the softening call geography. capital a in quarter, since reported our broad-based over uncertainty the has on the growth turned We industrial XX% we PMI of second business orders. earnings The our customers these last it to latter days with the more most in advanced in in hesitant to part for XXXX place of quarter markets in
actually gaining we're as phenomenon macroeconomic a environment. share purely is This this tough in
fourth the deteriorated semiconductor particularly also Motion XX% to temporary bookings declines further Slowing the felt XX%. We for quarter as Microelectronics and Photonics this of feel see for to third is our and quarter. Precision strengthening bookings in markets we were segments.
bottom We second modest expect half uptick XXXX. with to in a these in markets the
aim reminder, and a exposed and Novanta's microelectronics reduce exposure XX% microelectronics, the organically to we is markets As further M&A. to our to through revenue of strategically,
trade China Asia region were uncertainty the and the Pacific customer wars felt Geographically, Germany. the with and in particularly resulting
in China material declines processing Photonics declined our than and by our where market offset through microelectronics in industrial revenue sales year-to-date was Our more by XX%, growth medical segment.
and have at meaningful reminder, declines our a of overall while exposure impact China for modest, XX% the contributions Novanta comparison. level to relatively are Novanta Microelectronics China And year-over-year As enough an revenue. is are
declining a in did growing job teams Europe, tremendous environment. market a industrial in Our
we as temporary While weakness wavering in trimming and are not growth or our this technically manufacturing business weak area, in cycle. costs see do we investments expand waving through proprietary -- of the conviction our innovation technology positions to in our
very fact, cycle. of we matter see an a we are through to the gain positioned well share opportunity feel As and
year. with time, Now segment to which of let carrying me Vision into segments. quarter strong the our growth was, Starting star with the rest operating the this again, the momentum absolute turn this
diagnostics predominantly surgery the device. future reminder, the minimally applications include a As Vision market. and better segment medical serves invasive medical Large in
growth. year-over-year vision new be quarter, For sales versus the design In and last our revenue new launches products new product to Growth XX% the increased second XX% about delivered year, continue increased product wins Vision to year-to-date driven XX%, customers. revenue segment total new over segment, XX% at year-to-date. product and grew of by excellent revenue
timing. was The well segment new we progress to the launch expect XXXX. see previously due which The as predominantly as medical our order continue we we market, solid and in as to bill vision mainly market X.XX, through segment product momentum book momentum, vision mentioned, to as serves
the up new second and FMXXX XXXX, product depth The integrated in the quarter last smoke from of innovation, this a one with continuing did few with tremendous couldn't innovations, and its job the team strength of WOM relationships of WOM the evacuation. for the be in demand keeping performed the their Our extremely business superb insufflator business. pleased more quarters. well momentum We customer with
the the per devices. of XX Worldwide, laws tissue U.S., passed of and approximately to requiring pending evacuation is XX have been equates a are by day. procedures. all or smoke smoke with cigarettes dangerous during Surgical surgical XX% the Inhaling in of smoke devices product to vaporization energy-based smoking
Island laws example, being U.S., and U.K., and Massachusetts Denmark For the pending. Australia, passed Colorado in California Canada, Rhode in with are the and in
in product box. optimizing insufflator workflow separate and FMXXX a smoke-evacuation not evacuation smoke and filtering Our innovation functionality insufflator, integrates requiring the
business WOM represents year. uniquely to opportunity, capitalize is which positioned we growth believe market this Our market XX% of on per a
invasive of surgery visited minimally excited business extremely and the Finally, the and and Robert I the we are surgery WOM facilities, just funnel about and and markets. innovation robotic broader opportunity WOM overall
by pleased video product, room NDS XXth integrated delivered as very we're revenue the new addresses growth, consecutive driven VIMA, image on, year-over-year market. products our quarter. operating our second and acquisition and XK with which of product management core continued such quarter momentum wireless the the line Moving in or products NDS displays, new its of
In addition, profitability. the NDS its business substantially improved
position our technology market. in the acquisition and X we the from Change complementarity it customer further fits mentioned superbly perspective, Med earlier, As a improve OR feel integrated and will a
Finally, and see growth business of our around of to vision for continues strong Detection new product second expected machine while full the RFID & in show XXXX, with to business product in vision RFID continued launches product In with double-digit RFID the medical-grade offerings product machine date solid offerings. momentum quarter Analysis expanding and introductions year. total to its new X X revenue, its the
year-over-year surgery the robotic in Precision offset declined Our X% in momentum declines where segment second in Motion quarter, and steep could semiconductor. revenue not microelectronics fantastic growth
and and long-term dynamics invest We markets excited our markets. motion control robotics, remained share continue structure potential therefore, on We, as and strategy, multiple mid- innovation like metrology automation, growth these surgery dynamic as to this precise the in position markets precision about through gain such our we technologies, and segment. are in in to focused M&A with serving robotic
Motion to in we more wins as grew XX% bring our over Within by quarter our offset The and earlier, versus surgery. industrial than year innovations year-to-date, market Precision commercial teams. in new XX%, grew strong mentioned revenue X.XX Precision the was segment, and expanding to the are microelectronics market that the bill robotic softness momentum design Motion new to product last due we book and second partly
motion a As to allows stated capability that before, we critical customers. us our subsystem acquisition, now solutions adds intelligent to which offer the control are Ingenia excited about
dynamics Photonics our few Laser industrial revenue driven sequencing of revenue in capital-spending declined Turning year-over-year widely DNA by laser down quantum expected due climate. X%, to performance as in double-digit deteriorating quarters. we last and the second the reported the was the segment, the to on quarter in quantum
anticipated. is the the nor demand, second extent the our safety pronounced of sequencing very is the numerous sequencing as this sequencing DNA risk is clinical more competitive through penetration business be to we our double-digit stages quarter, our and And in of stock by fourth lumpiness on long-term to excitement the expected we catalysts look than in at down with long-term short-term was early and correlated customer modeled prospects We DNA horizon. mitigation quarter. flat this Brexit in third growth the the DNA As in believe half, not temporary recovering into position. market growth still with We about positive of applications reiterate now
segment the business discussed, Photonics of the macroeconomic industrial that Synrad performance of we is also was capital by The to. sensitive impacted headwinds spending our and which particularly just in some
expect a be on third growth improvement fourth this drag to our the with quarter. in the gradual We in quarter
The headwinds impacted be product Synrad. primarily the to revenue mid-single-digits declined in declined, mentioned Photonics Design we driven growth wins this our temporary. new laser also expect by above strategic quantum year-to-date, segment. temporarily KPIs in Year-to-date, Photonics and but
July. full double-digit design in As year and a of of wins as line design strong were few growth strong on fact, booked we matter already a have sight
Overall, in of second quarter uncertain and I'm revenue more that XXXX, we're organic growth the teams teams environment. agility in of the capital-spending with a proud very and profitability pleased of achieved industrial our our the
on To approach we Novanta sustainable advanced business wrap combined of through in our for disciplined expand long-term remain proprietary providing is industrial solid our M&A our is are and to conviction leadership up, to medical uncertain growth. innovation positions the macroeconomic our to Novanta's very medical focused environment. technology we markets a market an investments position well and and wavering not expand diversified grow foundation across in feel cycle. with in Therefore, positioned strategy
Robert turn call will Robert? to over our I more provide on details to the performance. that, financial with So
